Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
复制标题
急性肺损伤与急性呼吸窘迫综合征的药物治疗
DOI：
10.1177/0885066606287045
复制
发表时间：
2006-05-01
影响因子：
3.1
通讯作者：
Matthay, Michael A
中科院分区：
文献类型：
--
作者：
Cepkova, Magda;Matthay, Michael A
急性肺损伤和急性呼吸窘迫综合征是常见的综合征，死亡率很高，内科和外科患者都会受到影响。自1967年首次描述急性肺损伤和急性呼吸窘迫综合征以来，对急性肺损伤和急性呼吸窘迫综合征病理生理学的更好理解以及支持性护理和机械通气方面的进展导致了临床结果的改善。尽管已经对急性肺损伤和急性呼吸窘迫综合征患者进行了几种有前景的药物治疗，包括表面活性物质、一氧化氮、糖皮质激素和赖氨酸，但这些药物治疗都没有降低死亡率。本文概述了临床试验中测试的急性肺损伤和急性呼吸窘迫综合征的药物治疗，以及目前对其使用的建议，并讨论了未来可能的药物治疗，包括β(2)-肾上腺素能激动剂治疗、角质形成细胞生长因子和激活蛋白C。
Acute lung injury and the acute respiratory distress syndrome are common syndromes with a high mortality rate that affect both medical and surgical patients. Better understanding of the pathophysiology of acute lung injury and the acute respiratory distress syndrome and advances in supportive care and mechanical ventilation have led to improved clinical outcomes since the syndrome was first described in 1967. Although several promising pharmacological therapies, including surfactant, nitric oxide, glucocorticoids and lysofylline, have been studied in patients with acute lung injury and the acute respiratory distress syndrome, none of these pharmacological treatments reduced mortality. This article provides an overview of pharmacological therapies of acute lung injury and the acute respiratory distress syndrome tested in clinical trials and current recommendations for their use as well as a discussion of potential future pharmacological therapies including beta(2)-adrenergic agonist therapy, keratinocyte growth factor, and activated protein C.